NRG Oncology Network Group Operations Center

NRG 肿瘤网络集团运营中心

• 批准号: 10378672
• 负责人: NORMAN WOLMARK
• 金额: $ 547.74万
• 依托单位: NRG ONCOLOGY FOUNDATION, INC.
• 依托单位国家: 美国
• 财政年份: 2014
• 资助国家: 美国
• 起止时间: 2014-04-17 至 2025-02-28
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10378672
• 关键词: Adolescent and Young Adult; African ancestry; Alaska Native; American; Clinical Research; Communication; Country; Credentialing; Discipline of Nursing; Disease; Enrollment; General Population; Grant; Guidelines; Hispanic; Image; Latino; Malignant Neoplasms; Mission; Monitor; Monitoring Clinical Trials; National Clinical Trials Network; Native Americans; Native Hawaiian; Oncology; Pacific Islander; Patients; Performance; Process; Protocols documentation; Puerto Rico; Radiation Oncology; Radiation therapy; Review Committee; Science; Site; Time; Translational Research; Underrepresented Populations; Update; Washington; base; data quality; health disparity; improved; innovation; member; oncology trial; operation; programs; quality assurance; rare cancer

Member Site Core Abstract NRG Oncology (NRG) has established a large and diverse membership that includes 220 Tier 1 (Main Members) and 1188 Tier 2 enrolling sites. NRG Main Members and affiliates are located in all 50 states, Washington, DC, and Puerto Rico. There are 16 Canadian Main Members and 12 Non-North American Main Members located in 8 countries. NRG Oncology has the largest membership base of the groups in the NCI National Clinical Trials Network (NCTN), and NRG members also contribute the highest percentage of patients to the NCTN. For the period of March 1, 2014, through August 31, 2017, NRG trial accrual plus accrual to other NCTN group trials credited to NRG by its members represents approximately a third of the total NCTN accrual for that grant period. Of the 9,000 American patients enrolled on NRG trials during this time period, 12.7% self-identified as of African descent, 8.0% as Hispanic or Latino, and 1.3% as Native Hawaiian, other Pacific Islander, Native American, or Alaska native.. NRG has developed an audit program which is in compliance with the guidelines established by the NCI's Clinical Trials Monitoring Branch (CTMB). In addition, NRG carefully evaluates protocol accrual and data quality, a practice which enables the group to identify and intervene when underperforming centers are identified. NRG has developed a variety of accrual enhancement efforts including: the NRG Protocol Support Committee that reviews all proposed protocols relative to nursing and non-nursing matters; the NRG Health Disparities Committee whose primary aim is to increase enrollment of underrepresented populations to NRG trials; the Communications Committee which provides updates to the NRG members and general public promoting NRG activities and trials; the Center for Innovation in Radiation Oncology (CIRO) which assists NRG members with radiotherapy and imaging quality assurance process, including site qualification, credentialing and case reviews; and a Toll-Free 800 Line available for NRG members to obtain answers to protocol related questions. NRG cancer disease site committees have developed successful programs for patients with rare tumors and trials that provide an opportunity to enroll adolescent and young adult patients.

成员站点核心摘要 NRG肿瘤学（NRG）已经建立了一个大而多样化的成员资格，其中包括220层 （主要成员）和1188 Tier 2注册站点。 NRG主要成员和分支机构位于 在所有50个州，华盛顿特区和波多黎各。有16位加拿大主要成员， 12个非北美主要成员位于8个国家。 NRG肿瘤学有最大的 NCI国家临床试验网络（NCTN）和NRG中这些组的成员基础 成员还为NCTN贡献了最高百分比的患者。在 2014年3月1日，至2017年8月31日，NRG试用期应计入其他NCTN组 其成员归功于NRG的试验约占NCTN总的三分之一 该赠款期的应计。在此期间参加NRG试验的9,000名美国患者中 时间段为12.7％的自我识别为非洲血统，8.0％为西班牙裔或拉丁裔，1.3％ 作为夏威夷原住民，其他太平洋岛民，美国原住民或阿拉斯加本地人。 制定了一个符合NCI制定的准则的审计计划 临床试验监测分支（CTMB）。此外，NRG仔细评估协议应计 和数据质量，一种实践，使小组能够识别和干预 确定表现不佳的中心。 NRG开发了多种应计增强 努力包括：NRG协议支持委员会，审查所有提议的协议 相对于护理和非护理事务； NRG健康差异委员会 主要目的是增加NRG试验代表人群不足的入学人数；这 向NRG成员和公众提供更新的通信委员会 促进NRG活动和试验；辐射肿瘤学创新中心（CIRO） 这有助于NRG成员进行放疗和成像质量保证过程， 包括网站资格，证书和案例审查；还有免费的800线 供NRG成员获得有关协议相关问题的答案。 NRG癌症部位 委员会为患有罕见肿瘤和试验的患者制定了成功的计划 提供了入学青少年和年轻患者的机会。